Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and potentially other addictions, today announced that the first subject has been dosed in a Phase 2a smoking cessation study for the treatment of tobacco use disorder. EMB-001 is designed to help patients struggling with addiction maintain abstinence and improve their quality of life by simultaneously targeting multiple neurological pathways that play a role in stress-induced, cue-induced and drug-induced addiction relapse. Embera also announced that Dennis Purcell, the Founder of Aisling Capital, has joined the Board of Directors.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine and potentially other addictions, today announced that the first subjects have begun dosing of EMB-001 in a Phase 2 study for cocaine use disorder. EMB-001 is being tested to help patients struggling with addiction to maintain abstinence and improve their quality of life by simultaneously targeting multiple neurological pathways that play a role in stress-induced, cue-induced and drug-induced addiction relapse. Embera is developing the first medication that treats addiction by moderating activity in the stress response system.
BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced completion of its Series B financing and the receipt of two grant awards which will fund Phase 2 clinical studies for EMB-001 in cocaine use disorder and smoking cessation. EMB-001 is designed to help patients struggling with addiction to maintain abstinence and improve their quality of life by simultaneously targeting multiple neurological pathways that play a role in stress-induced, cue-induced and drug-induced addiction relapse.